Krystal Biotech, Inc. Common Stock vs. Novavax Inc
Krystal Biotech, Inc. Common Stock (KRYS) comes out ahead, leading on 5 of 8 compared factors.
Size & Scale
| KRYS | NVAX | |
|---|---|---|
| Market Cap | $10.65 billion | $1.49 billion |
| Revenue (TTM) | $440.48 million | $413.80 million |
| Net Income (TTM) | $241.47 million | $-247,730,000 |
KRYS leads on 3 of 3 size & scale factors.
Valuation
| KRYS | NVAX | |
|---|---|---|
| P/E Ratio | 44.79 | — |
| Price / Book | 7.83 | -7.83 |
| Price / Sales | 24.17 | 3.61 |
NVAX leads on 2 of 2 valuation factors.
Profitability
| KRYS | NVAX | |
|---|---|---|
| Net Margin | 54.82% | -59.87% |
| Return on Equity | 17.77% | 129.90% |
KRYS and NVAX split the profitability factors evenly.
Dividend
| KRYS | NVAX | |
|---|---|---|
| Dividend Yield | — | 14.09% |
KRYS and NVAX split the dividend factors evenly.
Risk & Sentiment
| KRYS | NVAX | |
|---|---|---|
| Short Interest | 0.11% | 25.98% |
KRYS leads on 1 of 1 risk & sentiment factors.
Dig deeper: KRYS overview, KRYS financials, NVAX overview, NVAX financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.